Nightstar Therapeutics Reports First Quarter 2018 Financial Results and Acceleration of Preliminary NSR-RPGR Readout to Third Quarter 2018
June 06, 2018 06:35 ET
|
Nightstar Therapeutics
Preliminary data from dose escalation study in the Phase 1/2 XIRIUS trial for X-Linked Retinitis Pigmentosa expected ahead of schedule in Q3 2018 Dose expansion study in the XIRIUS trial expected to...
Nightstar Therapeutics to Present at Jefferies 2018 Global Healthcare Conference
May 31, 2018 06:30 ET
|
Nightstar Therapeutics
LEXINGTON, Mass. and LONDON, May 31, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal...
Nightstar Therapeutics to Present at the Deutsche Bank 43rd Annual Health Care Conference
April 30, 2018 06:30 ET
|
Nightstar Therapeutics
LEXINGTON, Mass. and LONDON, April 30, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal...
Nightstar Therapeutics to Present New Data in Choroideremia at the ARVO 2018 Annual Meeting
April 23, 2018 06:30 ET
|
Nightstar Therapeutics
LEXINGTON, Mass. and LONDON, April 23, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal...
Nightstar Therapeutics Reports 2017 Financial Results and Business Highlights
April 03, 2018 17:15 ET
|
Nightstar Therapeutics
- Recent initiation of STAR phase 3 trial in Choroideremia - - Begins 2018 with a cash position over $129 million - LEXINGTON, Mass. and LONDON, April 03, 2018 (GLOBE NEWSWIRE) -- Nightstar...
Nightstar Therapeutics Announces Initiation of STAR Phase 3 Registrational Trial for NSR-REP1 in Choroideremia
March 05, 2018 06:30 ET
|
Nightstar Therapeutics
LEXINGTON, Mass. and LONDON, March 05, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal...
Nightstar Therapeutics to Participate in BMO Prescriptions for Success Healthcare Conference
December 07, 2017 06:30 ET
|
Nightstar Therapeutics
LEXINGTON, Mass. and LONDON, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal...
Nightstar Expands Pipeline with Novel Gene Therapy for the Treatment of Stargardt Disease
November 08, 2017 06:30 ET
|
Nightstar Therapeutics
Fourth Gene Therapy Program Targets the Most Common Inherited Juvenile Macular Dystrophy LEXINGTON, Mass. and LONDON, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Nightstar Therapeutics (NASDAQ:NITE), a...
Nightstar Therapeutics to Participate in Multiple Conferences in November
October 30, 2017 16:05 ET
|
Nightstar Therapeutics
LEXINGTON, Mass. and LONDON, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal...
Nightstar Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
October 02, 2017 16:05 ET
|
Nightstar Therapeutics
LEXINGTON, Mass. and LONDON, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (“Nightstar” or the “Company”) (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments...